These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

651 related items for PubMed ID: 26721204

  • 1. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A, Chen W, Pang J, Mi S, Li J, Guo W, Wang X, Gao J, Yu B, Shen Y, Xu Q.
    Cancer Lett; 2016 Mar 01; 372(1):82-8. PubMed ID: 26721204
    [Abstract] [Full Text] [Related]

  • 2. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Mar 01; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 3. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L, Liu H, Huang J, Xie W, Wei J, Ye X, Qian W.
    Oncotarget; 2017 Jan 31; 8(5):7777-7790. PubMed ID: 27999193
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gérard D, Lee JY, Mazumder A, Ahamed M, Christov C, Kim DW, Dicato M, Bormans G, Han BW, Diederich M.
    Clin Epigenetics; 2020 May 19; 12(1):69. PubMed ID: 32430012
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.
    Alvira D, Naughton R, Bhatt L, Tedesco S, Landry WD, Cotter TG.
    J Biol Chem; 2011 Sep 16; 286(37):32313-23. PubMed ID: 21795709
    [Abstract] [Full Text] [Related]

  • 9. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 10. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 11. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS.
    Cancer Lett; 2016 Dec 28; 383(2):220-229. PubMed ID: 27720778
    [Abstract] [Full Text] [Related]

  • 12. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H, Recio C, Martín-Acosta P, Guerra-Rodríguez M, Brito-Casillas Y, Blanco R, Junco V, León J, Montero JC, Gandullo-Sánchez L, McNaughton-Smith G, Zapata JM, Pandiella A, Amesty A, Estévez-Braun A, Fernández-Pérez L, Guerra B.
    Biomed Pharmacother; 2021 Dec 28; 144():112330. PubMed ID: 34673425
    [Abstract] [Full Text] [Related]

  • 13. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gérard D, Seidel C, Hahn H, Christov C, Dicato M, Kirsch G, Han BW, Schnekenburger M, Diederich M.
    Pharmacol Res; 2020 Oct 28; 160():105058. PubMed ID: 32619722
    [Abstract] [Full Text] [Related]

  • 14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 15. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H.
    Biomed Pharmacother; 2020 Sep 28; 129():110390. PubMed ID: 32563150
    [Abstract] [Full Text] [Related]

  • 16. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 28; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 17. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY, Liou JP, Lee YL, Lin JY, Huang HM.
    Invest New Drugs; 2017 Aug 28; 35(4):427-435. PubMed ID: 28349229
    [Abstract] [Full Text] [Related]

  • 18. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
    Wong SM, Liu FH, Lee YL, Huang HM.
    PLoS One; 2016 Aug 28; 11(1):e0148093. PubMed ID: 26815740
    [Abstract] [Full Text] [Related]

  • 19. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

  • 20. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM.
    Apoptosis; 2016 Sep 30; 21(9):1008-18. PubMed ID: 27344662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.